Ciaccia A
Department of Respiratory Tract Diseases and Physiology, University of Ferrara, Italy.
Arzneimittelforschung. 1994 Dec;44(12A):1516-20.
The efficacy of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) in the management of infectious exacerbations of chronic bronchitis was evaluated in a double-blind, placebo-controlled study in parallel groups over 5 months (60 days of treatment and 90 days of follow-up). The study enrolled 580 patients, of whom 514 could be evaluated. The pidotimod group had fewer and shorter infectious episodes, fewer days of antibiotic therapy and fewer days unable to undertake normal activities. The difference vs. placebo was significant during the follow-up period and, in those subjects with a less severe history, during the treatment period also. Pidotimod was well tolerated.
在一项为期5个月（60天治疗期和90天随访期）的双盲、安慰剂对照平行组研究中，评估了匹多莫德（(R)-3-[(S)-(5-氧代-2-吡咯烷基)羰基]-噻唑烷-4-羧酸，PGT/1A，CAS 121808-62-6）治疗慢性支气管炎感染性加重的疗效。该研究纳入了580例患者，其中514例可进行评估。匹多莫德组的感染发作次数更少、持续时间更短，抗生素治疗天数更少，无法进行正常活动的天数也更少。与安慰剂相比，在随访期以及病情较轻的患者的治疗期内，差异均具有显著性。匹多莫德耐受性良好。
